Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis
Jinqing Hu1, Huaiyuan Wang2, Jinfa Gu2
1Laboratory of Cell Biology, Xin-yuan Institute of Medicine and Biotechnology, School of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China.
Abstract:
Lung cancer has a high morbidity rate worldwide and is often resistant to therapy. Oncolytic virus therapy is a developing trend for cancer treatment. Thus, we constructed an oncolytic poxvirus carrying human trail gene that expresses a membrane-binding tumor necrosis factor and associated apoptosis-inducing ligand (TRAIL, Oncopox-trail). We hypothesized that the expression of trail would increase the efficacy of the oncolytic poxvirus. The effect of the TRAIL protein depends on the death receptors on the surface of different cancer cells. The expression of death receptors in lung cancer cell lines was analyzed by western blot analysis. In vitro, the oncolytic poxvirus carrying the trail gene displayed a better cytotoxicity at the cell level in the lung cancer cell line than that carrying the Oncopox-empty. TRAIL protein mainly induced apoptosis and inhibited necrosis. In vivo, two transplanted tumor models of human A549 lung cancer cells and mouse Lewis lung cancer cells were used to verify the anti-cancer effect of the oncolytic poxvirus carrying the trail gene. TUNEL staining results of the tumor histological sections also verified the anti-cancer effect. Similarly, through systemic administration of Oncopox-trail, the oncolytic poxvirus also exhibited anti-cancer effect.
Insights
Engineered oncolytic poxvirus expressing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) enhanced lung cancer cell killing. This novel therapy demonstrated significant anti-cancer effects in vitro and in vivo lung cancer models.
Area of Science:
- Oncolytic virology
- Cancer gene therapy
- Molecular oncology
Background:
- Lung cancer presents a significant global health burden with limited therapeutic options.
- Oncolytic virus therapy offers a promising new avenue for cancer treatment.
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediates cancer cell apoptosis via death receptors.
Purpose of the Study:
- To construct and evaluate an oncolytic poxvirus engineered to express TRAIL (Oncopox-trail) for enhanced lung cancer treatment.
- To investigate the efficacy of Oncopox-trail in preclinical lung cancer models.
- To determine if TRAIL expression augments the oncolytic activity of the poxvirus.
Main Methods:
- Western blot analysis to assess death receptor expression in lung cancer cell lines.
- In vitro cytotoxicity assays comparing Oncopox-trail with Oncopox-empty on lung cancer cells.
- In vivo studies using human A549 and mouse Lewis lung cancer xenograft models.
- TUNEL staining to evaluate apoptosis in tumor tissues.
Main Results:
- Oncopox-trail exhibited superior in vitro cytotoxicity against lung cancer cells compared to the control virus.
- TRAIL-mediated cell death was primarily through apoptosis, with minimal necrosis.
- In vivo administration of Oncopox-trail significantly inhibited tumor growth in both human and mouse lung cancer models.
- TUNEL staining confirmed increased apoptosis in tumors treated with Oncopox-trail.
Conclusions:
- Engineered oncolytic poxvirus expressing TRAIL (Oncopox-trail) demonstrates potent anti-cancer activity against lung cancer.
- TRAIL-expressing oncolytic virus represents a viable strategy to enhance therapeutic efficacy in lung cancer.
- Further investigation into Oncopox-trail for clinical application in lung cancer is warranted.
More Related Videos
Related Concept Videos
Apoptosis
Muscles that Move the Arm
The pectoralis major has two origins. Its clavicular head originates on the medial half of the clavicle. In contrast, the sternocostal head originates on the costal cartilages of ribs 1-6, the sternum, and the aponeurosis of the external oblique of the...
Mechanisms of Retrovirus-induced Cancers
Lung Capacity
Induced Pluripotent Stem Cells
Cancer Cell Migration through Invadopodia


